DNM1L: A Promising Drug Target / Biomarker (G10059)

Target Name: DNM1L

NCBI ID: G10059

DNM1L

DNM1L: A Promising Drug Target / Biomarker

Drug resistance is a major clinical issue that affects the effectiveness of antibiotics, particularly in the treatment of bacterial infections. One of the most common antibiotic-resistant bacteria is DNM1L, which is a type of Enterobacterium that can cause urinary tract infections and other types of infections. In this article, we will discuss DNM1L and its potential as a drug target or biomarker.

DNM1L: A Common Source of Urinary Tract Infections

Urinary tract infections (UTIs) are typically caused by bacteria that enter the urinary tract through a urinary tract opening, such as the urethra. DNM1L is a type of Enterobacterium that is commonly found in the gut and is associated with a high rate of UTIs. Studies have shown that DNM1L is present in the majority of UTIs and that it is the most commonly identified cause of UTIs in women.

DNM1L's Link to Urinary Tract Infections

The ability of DNM1L to cause UTIs has important implications for the treatment of these infections. Currently, the only treatment options for UTIs are antibiotics. However, the growing problem of antibiotic resistance has made it difficult to treat UTIs effectively. DNM1L, in particular, is a bacteria that is resistant to many commonly used antibiotics, making it a difficult target for treatment.

DNM1L's Potential as a Drug Target

Despite the challenges associated with treating UTIs, there is ongoing research into developing new and more effective antibiotics to treat these infections. One potential solution to this problem is the development of drug targets for UTIs. By identifying specific bacteria that are resistant to currently available antibiotics and targeting those bacteria with new treatments, researchers hope to improve the effectiveness of UTI treatments.

DNM1L is an attractive drug target for UTIs because it is a common source of UTIs and is resistant to many commonly used antibiotics. Studies have shown that DNM1L is resistant to commonly used antibiotics such as ciprofloxacin, a drug used to treat UTIs, and colistin, a drug that is often used to treat severe infections that are resistant to other antibiotics. This makes DNM1L a potential target for researchers to develop new and more effective UTI treatments.

DNM1L's Potential as a Biomarker

In addition to its potential as a drug target, DNM1L may also be a useful biomarker for the diagnosis and monitoring of UTIs. Currently, there are few biomarkers that can accurately predict the severity of a UTI or the likelihood of treatment success. This makes it difficult to monitor the effectiveness of UTI treatments and to determine when a patient may be at risk for complications.

DNM1L may be a useful biomarker for the diagnosis and monitoring of UTIs because it is present in the majority of UTIs and can be easily detected and measured. Studies have shown that DNM1L can be detected in urine samples from patients with UTIs and that it is associated with the severity of these infections. This makes DNM1L a potential biomarker for the diagnosis and monitoring of UTIs.

Conclusion

DNM1L is a common type of Enterobacterium that is associated with a high rate of UTIs. Its resistance to commonly used antibiotics makes it a difficult target for treatment, but its potential as a drug target or biomarker makes it an attractive target for researchers to develop new and more effective UTI treatments. Further research is needed to determine the full potential of DNM1L as a drug target and biomarker for the diagnosis and treatment of UTIs.

Protein Name: Dynamin 1 Like

Functions: Functions in mitochondrial and peroxisomal division (PubMed:9570752, PubMed:9786947, PubMed:11514614, PubMed:12499366, PubMed:17301055, PubMed:17553808, PubMed:17460227, PubMed:18695047, PubMed:18838687, PubMed:19638400, PubMed:19411255, PubMed:19342591, PubMed:23921378, PubMed:23283981, PubMed:23530241, PubMed:29478834, PubMed:32484300, PubMed:27145208, PubMed:26992161, PubMed:27301544, PubMed:27328748). Mediates membrane fission through oligomerization into membrane-associated tubular structures that wrap around the scission site to constrict and sever the mitochondrial membrane through a GTP hydrolysis-dependent mechanism (PubMed:23530241, PubMed:23584531). The specific recruitment at scission sites is mediated by membrane receptors like MFF, MIEF1 and MIEF2 for mitochondrial membranes (PubMed:23921378, PubMed:23283981, PubMed:29899447). While the recruitment by the membrane receptors is GTP-dependent, the following hydrolysis of GTP induces the dissociation from the receptors and allows DNM1L filaments to curl into closed rings that are probably sufficient to sever a double membrane (PubMed:29899447). Acts downstream of PINK1 to promote mitochondrial fission in a PRKN-dependent manner (PubMed:32484300). Plays an important role in mitochondrial fission during mitosis (PubMed:19411255, PubMed:26992161, PubMed:27301544, PubMed:27328748). Through its function in mitochondrial division, ensures the survival of at least some types of postmitotic neurons, including Purkinje cells, by suppressing oxidative damage (By similarity). Required for normal brain development, including that of cerebellum (PubMed:17460227, PubMed:27145208, PubMed:26992161, PubMed:27301544, PubMed:27328748). Facilitates developmentally regulated apoptosis during neural tube formation (By similarity). Required for a normal rate of cytochrome c release and caspase activation during apoptosis; this requirement may depend upon the cell type and the physiological apoptotic cues (By similarity). Required for formation of endocytic vesicles (PubMed:9570752, PubMed:20688057, PubMed:23792689). Proposed to regulate synaptic vesicle membrane dynamics through association with BCL2L1 isoform Bcl-X(L) which stimulates its GTPase activity in synaptic vesicles; the function may require its recruitment by MFF to clathrin-containing vesicles (PubMed:17015472, PubMed:23792689). Required for programmed necrosis execution (PubMed:22265414). Rhythmic control of its activity following phosphorylation at Ser-637 is essential for the circadian control of mitochondrial ATP production (PubMed:29478834)

The "DNM1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNM1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets